Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8757038rdf:typepubmed:Citationlld:pubmed
pubmed-article:8757038lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:8757038lifeskim:mentionsumls-concept:C0060135lld:lifeskim
pubmed-article:8757038lifeskim:mentionsumls-concept:C0064636lld:lifeskim
pubmed-article:8757038lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:8757038lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:8757038lifeskim:mentionsumls-concept:C1521738lld:lifeskim
pubmed-article:8757038lifeskim:mentionsumls-concept:C1519355lld:lifeskim
pubmed-article:8757038lifeskim:mentionsumls-concept:C0061838lld:lifeskim
pubmed-article:8757038pubmed:issue2lld:pubmed
pubmed-article:8757038pubmed:dateCreated1996-11-26lld:pubmed
pubmed-article:8757038pubmed:abstractTextWe studied the action of the new antiepileptic drugs lamotrigine (LTG), GP 47779 (the active metabolite of oxcarbazepine), and felbamate (FBM) on stimulus-evoked field potentials recorded from rat prefrontal and frontal cortical slices. In the presence of physiologic concentrations of extracellular magnesium (1.2 mM) the field potential amplitude was not affected by the N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, 2-amino-5-phosphonovalerate (APV), while it was blocked by the non-NMDA glutamate receptor antagonist, 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX). When magnesium was removed from the bathing medium, there was a significant NMDA-mediated component of the field potential. LTG and GP 47779 decreased, in a dose-dependent manner, the field potential amplitude under both experimental conditions. FBM caused a dose-related decrease of the field potential amplitude only in the absence of external magnesium, suggesting a selective interaction with an NMDA-mediated component of this potential. These findings indicate that the reduction of cortical excitatory transmission might represent a common target for new antiepileptic drugs.lld:pubmed
pubmed-article:8757038pubmed:languageenglld:pubmed
pubmed-article:8757038pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8757038pubmed:citationSubsetAIMlld:pubmed
pubmed-article:8757038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8757038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8757038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8757038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8757038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8757038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8757038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8757038pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8757038pubmed:statusMEDLINElld:pubmed
pubmed-article:8757038pubmed:monthAuglld:pubmed
pubmed-article:8757038pubmed:issn0028-3878lld:pubmed
pubmed-article:8757038pubmed:authorpubmed-author:BernardiGGlld:pubmed
pubmed-article:8757038pubmed:authorpubmed-author:CalabresiPPlld:pubmed
pubmed-article:8757038pubmed:authorpubmed-author:SiniscalchiAAlld:pubmed
pubmed-article:8757038pubmed:authorpubmed-author:StefaniAAlld:pubmed
pubmed-article:8757038pubmed:authorpubmed-author:PisaniAAlld:pubmed
pubmed-article:8757038pubmed:authorpubmed-author:MercuriN BNBlld:pubmed
pubmed-article:8757038pubmed:issnTypePrintlld:pubmed
pubmed-article:8757038pubmed:volume47lld:pubmed
pubmed-article:8757038pubmed:ownerNLMlld:pubmed
pubmed-article:8757038pubmed:authorsCompleteYlld:pubmed
pubmed-article:8757038pubmed:pagination557-62lld:pubmed
pubmed-article:8757038pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:8757038pubmed:meshHeadingpubmed-meshheading:8757038-...lld:pubmed
pubmed-article:8757038pubmed:meshHeadingpubmed-meshheading:8757038-...lld:pubmed
pubmed-article:8757038pubmed:meshHeadingpubmed-meshheading:8757038-...lld:pubmed
pubmed-article:8757038pubmed:meshHeadingpubmed-meshheading:8757038-...lld:pubmed
pubmed-article:8757038pubmed:meshHeadingpubmed-meshheading:8757038-...lld:pubmed
pubmed-article:8757038pubmed:meshHeadingpubmed-meshheading:8757038-...lld:pubmed
pubmed-article:8757038pubmed:meshHeadingpubmed-meshheading:8757038-...lld:pubmed
pubmed-article:8757038pubmed:meshHeadingpubmed-meshheading:8757038-...lld:pubmed
pubmed-article:8757038pubmed:meshHeadingpubmed-meshheading:8757038-...lld:pubmed
pubmed-article:8757038pubmed:meshHeadingpubmed-meshheading:8757038-...lld:pubmed
pubmed-article:8757038pubmed:meshHeadingpubmed-meshheading:8757038-...lld:pubmed
pubmed-article:8757038pubmed:meshHeadingpubmed-meshheading:8757038-...lld:pubmed
pubmed-article:8757038pubmed:year1996lld:pubmed
pubmed-article:8757038pubmed:articleTitleA field potential analysis on the effects of lamotrigine, GP 47779, and felbamate in neocortical slices.lld:pubmed
pubmed-article:8757038pubmed:affiliationClinica Neurologica, Università di Roma Tor Vergata, Italy.lld:pubmed
pubmed-article:8757038pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8757038pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8757038lld:pubmed